Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery

Kolacinska,Agnieszka; Cebula‑Obrzut,Barbara; Pakula,Lukasz; Chalubinska‑Fendler,Justyna; Morawiec‑Sztandera,Alina; Pawlowska,Zofia; Zawlik,Izabela; Morawiec,Zbigniew; Jesionek‑Kupnicka,Dorota; Smolewski,Piotr

doi:10.3892/ol.2015.3321

Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery

Authors:
- Agnieszka Kolacinska
- Barbara Cebula‑Obrzut
- Lukasz Pakula
- Justyna Chalubinska‑Fendler
- Alina Morawiec‑Sztandera
- Zofia Pawlowska
- Izabela Zawlik
- Zbigniew Morawiec
- Dorota Jesionek‑Kupnicka
- Piotr Smolewski
View Affiliations

Affiliations: Department of Head and Neck Cancer Surgery, Medical University of Łódź, Łódź 93‑509, Poland, Department of Experimental Hematology, Medical University of Łódź, Łódź 93‑510, Poland, Department of Anesthesiology, Copernicus Memorial Hospital, Łódź 93‑509, Poland, Department of Radiotherapy, Medical University of Łódź, Łódź 93‑509, Poland, Central Scientific Laboratory, Medical University of Łódź, Łódź 92‑215, Poland, Department of Medical Genetics, Institute of Nursing and Health Sciences, Faculty of Medicine, University of Rzeszów, Rzeszów 35‑959, Poland, Department of Surgical Oncology, Cancer Center, Łódź 93‑509, Poland, Department of Cancer Pathology, Medical University of Łódź, Łódź 93‑509, Poland
Published online on: June 4, 2015 https://doi.org/10.3892/ol.2015.3321
Pages: 1079-1086

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immune checkpoints refer to a plethora of inhibitory pathways built into the immune system, and recent studies have emphasized the role of these checkpoints in carcinogenesis. The aim of the present study was to evaluate two major immune checkpoints, the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD‑1), in the serum of 35 patients with stage I and II breast cancer. Serum concentrations of CTLA‑4 and PD‑1 were measured at three time points: i) Preoperatively; ii) during anesthesia following the harvesting of sentinel nodes (SNs); and iii) 24 h postoperatively. Control samples were obtained from 25 healthy, age‑matched females. Assessment of CTLA‑4 and PD‑1 expression levels was conducted using flow cytometry. A statistically significant difference in PD‑1 expression was identified between breast cancer patients preoperatively and healthy controls (26.31±11.87 vs. 12.72±8.15; P<0.0001). In addition, a statistically significant association was found between CTLA‑4 and PD‑1 levels prior to surgery (P=0.0084). In addition, CTLA‑4 expression was associated with age (P=0.0453), with elevated levels of CTLA‑4 detected in older breast cancer patients. Higher PD‑1 expression levels were observed in T2 tumors compared with T1 tumors prior to surgery and intraoperatively; however, the differences were not statistically significant. Furthermore, a decrease in PD‑1 levels was observed subsequent to harvesting SNs with metastasis, but not in SN‑negative patients (P=0.05). A negative correlation was also observed between PD‑1 expression and progesterone receptor (PR) status following surgery (P=0.024). These results provided a basis for further investigation of immune checkpoints in breast cancer. Breast cancer patients exhibit an altered profile of immune checkpoint markers, with higher concentrations of PD-1 observed in larger, PR-negative tumors.

View Figures

View References

1	Urban JA and Baker HW: Radical mastectomy in continuity with en bloc resection of the internal mammary lymph-node chain; a new procedure for primary operable cancer of the breast. Cancer. 5:992–1008. 1952. View Article : Google Scholar : PubMed/NCBI
2	Halsted WS: I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 20:497–555. 1894. View Article : Google Scholar : PubMed/NCBI
3	Giuliano AE, Kirgan DM, Guenther JM and Morton DL: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 220:391–398. 1994. View Article : Google Scholar : PubMed/NCBI
4	Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM and Morrow M: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 305:569–575. 2011. View Article : Google Scholar : PubMed/NCBI
5	Galimberti V, Cole BF, Zurrida S, et al International Breast Cancer Study Group Trial 23-01 investigators: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 14:297–305. 2013. View Article : Google Scholar : PubMed/NCBI
6	Gentilini O and Veronesi U: Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 21:678–681. 2012. View Article : Google Scholar : PubMed/NCBI
7	Reimer T, Hartmann S, Stachs A and Gerber B: Local treatment of the axilla in early breast cancer: Concepts from the national surgical adjuvant breast and bowel project B-04 to the planned intergroup sentinel mamma trial. Breast Care Basel. 9:87–95. 2014.PubMed/NCBI
8	Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI
9	Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
10	Ott PA, Hodi FS and Robert C: CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 19:5300–5309. 2013. View Article : Google Scholar : PubMed/NCBI
11	Eggermont AM, Spatz A and Robert C: Cutaneous melanoma. Lancet. 383:816–827. 2014. View Article : Google Scholar : PubMed/NCBI
12	Lipson EJ, Sharfman WH, Drake CG, et al: Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 19:462–468. 2013. View Article : Google Scholar : PubMed/NCBI
13	Loi S: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2⁺ BC). Presented at the. San Antonio Breast Cancer Symposium. 2013.https://www.conferencenotes.co/conferences/5467ecb588d6868d254609f6/presentations/54739f542e0507a22d1b9341?referrer=history
14	Beavis PA, Milenkovski N, Henderson MA, et al: Adenosine receptor 2A blockade increases the efficacy of anti-PD1 through enhanced antitumor T-cell responses. Cancer Immunol Res. Feb 11–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
15	Denkert C, von Minckwitz G, Brase JC, et al: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 33:983–991. 2015. View Article : Google Scholar : PubMed/NCBI
16	Verbrugge I, Hagekyriakou J, Sharp LL, et al: Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 72:3163–3174. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bos PD, Plitas G, Rudra D, Lee SY and Rudensky AY: Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med. 210:2435–2466. 2013. View Article : Google Scholar : PubMed/NCBI
18	Vonderheide RH, LoRusso PM, Khalil M, et al: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 16:3485–3494. 2010. View Article : Google Scholar : PubMed/NCBI
19	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
20	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI
21	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
22	Legat A, Speiser DE, Pircher H, Zehn D and Fuertes Marraco SA: Inhibitory receptor expression depends more dominantly on differentiation and activation than “exhaustion” of human CD8 T cells. Front Immunol. 4:4552013. View Article : Google Scholar : PubMed/NCBI
23	Poschke I, De Boniface J, Mao Y and Kiessling R: Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients. Int J Cancer. 131:1611–1620. 2012. View Article : Google Scholar : PubMed/NCBI
24	Azim HA, Brohée S, Peccatori FA, et al: Biology of breast cancer during pregnancy using genomic profiling. Endocr Relat Cancer. 21:545–554. 2014. View Article : Google Scholar : PubMed/NCBI
25	Poland GA, Ovsyannikova IG, Kennedy RB, Lambert ND and Kirkland JL: A systems biology approach to the effect of aging, immunosenescence and vaccine response. Curr Opin Immunol. 29:62–68. 2014. View Article : Google Scholar : PubMed/NCBI
26	Martinet KZ, Bloquet S and Bourgeois C: Ageing combines CD4 T cell lymphopenia in secondary lymphoid organs and T cell accumulation in gut associated lymphoid tissue. Immun Ageing. 11:82014. View Article : Google Scholar : PubMed/NCBI
27	Stagg J, Andre F and Loi S: Immunomodulation via chemotherapy and targeted therapy: A new paradigm in breast cancer therapy? Breast Care Basel. 7:267–272. 2012. View Article : Google Scholar : PubMed/NCBI
28	Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 28:3167–3175. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
30	Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
31	National Comprehensive Cancer Network, . Clinical Practice Guidelines in Oncology. Version 2. 2015 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breastAccessed. March 11–2015
32	Vallacchi V, Vergani E, Camisaschi C, et al: Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Cancer Res. 74:130–140. 2014. View Article : Google Scholar : PubMed/NCBI
33	Goldhirsch A, Winer EP, Coates AS, et al: Role: Panel membersPersonalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
34	Prat A, Cheang MC, Martín M, et al: Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 31:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
35	Carroll JS: Steroids, nuclear receptors and breast cancer. Preface. Mol Cell Endocrinol. 382:6232014. View Article : Google Scholar : PubMed/NCBI
36	Denkert C: The immunogenicity of breast cancer - molecular subtypes matter. Ann Oncol. 25:1453–1455. 2014. View Article : Google Scholar : PubMed/NCBI
37	Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
38	von Minckwitz G, Schneeweiss A, Loibl S, et al: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 15:747–756. 2014. View Article : Google Scholar : PubMed/NCBI
39	Denkert C: Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer. J Clin Oncol. 31:836–837. 2013. View Article : Google Scholar : PubMed/NCBI
40	Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI